# Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

> **NCT04735861** · PHASE2 · COMPLETED · sponsor: **Tongji Hospital** · enrollment: 38 (actual)

## Conditions studied

- Ovarian Clear Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab Biosimilar IBI305

## Key facts

- **NCT ID:** NCT04735861
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-07
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-08-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735861, "Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04735861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*